Being started on a smaller dose of the approved early Alzheimer’s disease therapy Kisunla (donanemab) — by shifting one vial from the first to the third infusion treatment — reduces the risk of ARIA-E, or amyloid-related imaging abnormalities associated with brain swelling, among adults with the neurodegenerative condition. That’s…
Sage Therapeutics plans to stop developing dalzanemdor (SAGE-718) for Alzheimer’s disease after the treatment failed to meet the main goal of improving cognitive function in a Phase 2 study in patients with mild cognitive impairment or mild dementia. In the LIGHTWAVE study (NCT05619692), patients treated with dalzanemdor didn’t…
Higher exposure to outdoor light at night may increase the risk of developing Alzheimer’s disease, especially in people younger than 65, according to a study that drew on Medicare records and satellite-based light pollution maps. “Average nighttime light intensity was more strongly associated with [Alzheimer’s disease] prevalence than some…
September is awareness month for Alzheimer’s disease and other forms of dementia, and Alzheimer’s Disease International (ADI) is calling on the disease to be made a global health priority with the theme, “Time to act on dementia, time to act on Alzheimer’s.” Several initiatives have been held…
Fosgonimeton, an investigational medication from Athira Pharma, failed to significantly improve cognitive and daily functioning in adults with mild to moderate Alzheimer’s disease who took part in a Phase 2/3 clinical trial, despite being safe and well tolerated, top-line data show. “These are not the results we hoped…
Data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) study, the first and largest to focus on people who have early signs of Alzheimer’s disease but are not yet showing symptoms, are now available to researchers around the world. Recognizing a need for starting treatment before any symptoms appear,…
Nearly one year of treatment with blarcamesine (Anavex 2-73), a once-daily oral small molecule being developed by Anavex Life Sciences, slowed cognitive and functional decline in people with early Alzheimer’s disease, according to data from a global Phase 2b/3 clinical study. Researchers also observed that patients on…
Foralumab, an investigational nasal spray being developed by Tiziana Life Sciences, has been cleared by the U.S. Food and Drug Administration (FDA) for expanded use to treat moderate Alzheimer’s disease, and the first patient is expected to be dosed soon. An expanded use program, also called a compassionate…
Treatment with buntanetap, a small molecule being developed by Annovis Bio for neurodegenerative diseases, improved cognitive function in people with mild Alzheimer’s positive for certain disease biomarkers, especially in earlier stages of the disease. These are findings from a Phase 2/3 clinical study (NCT05686044) in which 353…
Treatment with SNK01, a natural killer (NK) cell therapy being developed by NKGen Biotech, appears safe and well tolerated and may offer a cognitive benefit to people with Alzheimer’s disease, according to data from a small Phase 1 clinical trial. Given directly into the bloodstream, SNK01 was able…
Get regular updates to your inbox.